FeRx Incorporated

The Company is focused on the development and commercialization of its proprietary Magnetic Targeted Carrier ("MTC") technology for the site specific delivery and sustained release of pharmaceutical agents. FeRx's lead compound, MTC-Doxorubicin, is in Phase I/II clinical trials in patients with liver cancer.

Contact Details: Tel: Fax: Email: WWW: www.ferx.com/

Recent Publications by FeRx Incorporated:
Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. PURPOSE: The feasibility of using magnetic targeted carriers (MTC) to...	30th July, 2003	FeRx Inc., 9171 Towne Centre Dr., Ste. 575, San Diego, CA 92122, USA.	Cancer Chemother Pharmacol. 2003 Jun;51(6):445-50. Epub 2003 Mar 22. DOI Direct Link

FeRx Incorporated Clinical Trials:
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

FeRx Incorporated Patents:
US Patent No.	Title
6663555	Permanent magnet keeper-shield assembly
6488615	Permanent magnet keeper-shield assembly
6482436	Magnetically responsive composition
6200547	Magnetically responsive compositions for carrying biologically active substances and methods of production and use

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 1017 times since April 2007, the link to the organisation's website has been followed 287 times

Recent Search Terms used to find this page: ferx clinical pdf | FeRx Incorporated | FeRx | FeRX Incorporated | FERX incorporated | Ferx Incorporated | ferx patent | FeRx Doxorubicin | ferx | FeRX Incorporated | .

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for FeRx Incorporated